{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:13:33Z","timestamp":1791994413571,"version":"4.4.0"},"reference-count":65,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Beh\u00f6rde f\u00fcr Wissenschaft, Forschung, Gleichstellung und Bezirke of the Freie und Hansestadt Hamburg"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Emerging influenza A viruses (IAV) bear the potential to cause pandemics with unpredictable consequences for global human health. In particular, the WHO has declared avian H5 and H7 subtypes as high-risk candidates, and continuous surveillance of these viruses as well as the development of novel, broadly acting antivirals, are key for pandemic preparedness. In this study, we sought to design T-705 (Favipiravir) related inhibitors that target the RNA-dependent RNA polymerase and evaluate their antiviral efficacies against a broad range of IAVs. Therefore, we synthesized a library of derivatives of T-705 ribonucleoside analogues (called T-1106 pronucleotides) and tested their ability to inhibit both seasonal and highly pathogenic avian influenza viruses in vitro. We further showed that diphosphate (DP) prodrugs of T-1106 are potent inhibitors of H1N1, H3N2, H5N1, and H7N9 IAV replication. Importantly, in comparison to T-705, these DP derivatives achieved 5- to 10-fold higher antiviral activity and were non-cytotoxic at the therapeutically active concentrations. Moreover, our lead DP prodrug candidate showed drug synergy with the neuraminidase inhibitor oseltamivir, thus opening up another avenue for combinational antiviral therapy against IAV infections. Our findings may serve as a basis for further pre-clinical development of T-1106 prodrugs as an effective countermeasure against emerging IAVs with pandemic potential.<\/jats:p>","DOI":"10.3390\/pharmaceutics15061732","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T01:32:57Z","timestamp":1686792777000},"page":"1732","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["T-705-Derived Prodrugs Show High Antiviral Efficacies against a Broad Range of Influenza A Viruses with Synergistic Effects When Combined with Oseltamivir"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0128-5318","authenticated-orcid":false,"given":"Benedikt","family":"Ganter","sequence":"first","affiliation":[{"name":"Organic Chemistry, Department of Chemistry, Faculty of Sciences, Hamburg University, 20146 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Zickler","sequence":"additional","affiliation":[{"name":"Department for Viral Zoonoses-One Health, Leibniz Institute of Virology, 20251 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6368-3273","authenticated-orcid":false,"given":"Johanna","family":"Huchting","sequence":"additional","affiliation":[{"name":"Organic Chemistry, Department of Chemistry, Faculty of Sciences, Hamburg University, 20146 Hamburg, Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, 22525 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Winkler","sequence":"additional","affiliation":[{"name":"Organic Chemistry, Department of Chemistry, Faculty of Sciences, Hamburg University, 20146 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"L\u00fcttjohann","sequence":"additional","affiliation":[{"name":"Department for Viral Zoonoses-One Health, Leibniz Institute of Virology, 20251 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Meier","sequence":"additional","affiliation":[{"name":"Organic Chemistry, Department of Chemistry, Faculty of Sciences, Hamburg University, 20146 Hamburg, Germany"},{"name":"German Center for Infection Research (DZIF), 38124 Braunschweig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclsah","family":"Gabriel","sequence":"additional","affiliation":[{"name":"Department for Viral Zoonoses-One Health, Leibniz Institute of Virology, 20251 Hamburg, Germany"},{"name":"German Center for Infection Research (DZIF), 38124 Braunschweig, Germany"},{"name":"Institute of Virology, University of Veterinary Medicine Hannover, 30559 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Beck","sequence":"additional","affiliation":[{"name":"Department for Viral Zoonoses-One Health, Leibniz Institute of Virology, 20251 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"key":"ref_1","unstructured":"(2023, March 24). Influenza (Seasonal). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal)."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1016\/j.cell.2021.08.017","article-title":"The origins of SARS-CoV-2: A critical review","volume":"184","author":"Holmes","year":"2021","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/bmj.p401","article-title":"H5N1: Do we need to worry about the latest bird flu outbreaks?","volume":"380","author":"Mahase","year":"2023","journal-title":"BMJ"},{"key":"ref_4","first-page":"Doc02","article-title":"Prophylaxis and treatment of influenza: Options, antiviral susceptibility, and existing recommendations","volume":"9","author":"Duwe","year":"2021","journal-title":"GMS Infect. Dis."},{"key":"ref_5","first-page":"Doc04","article-title":"Influenza viruses-antiviral therapy and resistance","volume":"5","author":"Duwe","year":"2017","journal-title":"GMS Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3201\/eid2206.151037","article-title":"Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza","volume":"22","author":"Hurt","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"104545","DOI":"10.1016\/j.antiviral.2019.104545","article-title":"Antivirals targeting the polymerase complex of influenza viruses","volume":"169","author":"Mifsud","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1021\/jm5007275","article-title":"Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1021\/acs.molpharmaceut.8b00531","article-title":"A Small-Molecule Compound Has Anti-influenza A Virus Activity by Acting as a \u201cPB2 Inhibitor\u201d","volume":"15","author":"Liu","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6444","DOI":"10.1021\/acs.jmedchem.6b00628","article-title":"Fragment-Based Identification of Influenza Endonuclease Inhibitors","volume":"59","author":"Credille","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1021\/acs.jmedchem.5b00012","article-title":"A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Subunits","volume":"58","author":"Massari","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8086","DOI":"10.1021\/jm500958x","article-title":"Phenyl substituted 4-hydroxypyridazin-3(2H)-ones and 5-hydroxypyrimidin-4(3H)-ones: Inhibitors of influenza A endonuclease","volume":"57","author":"Sagong","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1021\/acs.jmedchem.1c01257","article-title":"Discovery of Aryl Benzoyl Hydrazide Derivatives as Novel Potent Broad-Spectrum Inhibitors of Influenza A Virus RNA-Dependent RNA Polymerase (RdRp)","volume":"65","author":"Liu","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1038\/s41598-018-20772-9","article-title":"Identification of influenza polymerase inhibitors targeting C-terminal domain of PA through surface plasmon resonance screening","volume":"8","author":"Lo","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ahmad, H., Zia, B., Husain, H., and Husain, A. (2023). Recent Advances in PROTAC-Based Antiviral Strategies. Vaccines, 11.","DOI":"10.3390\/vaccines11020270"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.1021\/acs.jmedchem.1c02013","article-title":"Discovery of Pentacyclic Triterpenoid PROTACs as a Class of Effective Hemagglutinin Protein Degraders","volume":"65","author":"Li","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"100030","DOI":"10.1016\/j.cellin.2022.100030","article-title":"Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus","volume":"1","author":"Xu","year":"2022","journal-title":"Cell Insight."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (Favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"104529","DOI":"10.1016\/j.antiviral.2019.06.001","article-title":"T-705 induces lethal mutagenesis in Ebola and Marburg populations in macaques","volume":"170","author":"Espy","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"26955","DOI":"10.1073\/pnas.2014441117","article-title":"Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity","volume":"117","author":"Kaptein","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/dmp.2014.151","article-title":"Favipiravir: A new medication for the Ebola virus disease pandemic","volume":"9","author":"Nagata","year":"2015","journal-title":"Disaster. Med. Public Health Prep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/infdis\/jiac135","article-title":"Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials","volume":"226","author":"Hayden","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/cmdc.201700116","article-title":"Synthesis of T-705-Ribonucleoside and T-705-Ribonucleotide and Studies of Chemical Stability","volume":"12","author":"Huchting","year":"2017","journal-title":"ChemMedChem"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2019.04.002","article-title":"Cell line-dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (Favipiravir)","volume":"167","author":"Huchting","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1021\/acs.jmedchem.8b00617","article-title":"Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors","volume":"61","author":"Huchting","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"111901","DOI":"10.1016\/j.celrep.2022.111901","article-title":"Direct observation of backtracking by influenza A and B polymerases upon consecutive incorporation of the nucleoside analog T1106","volume":"42","author":"Kouba","year":"2023","journal-title":"Cell Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1002\/anie.201511808","article-title":"Membrane-permeable Triphosphate Prodrugs of Nucleoside Analogues","volume":"55","author":"Gollnest","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.chom.2017.02.020","article-title":"Pregnancy-Related Immune Adaptation Promotes the Emergence of Highly Virulent H1N1 Influenza Virus Strains in Allogenically Pregnant Mice","volume":"21","author":"Engels","year":"2017","journal-title":"Cell Host Microbe"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/ncomms1158","article-title":"Differential use of importin-alpha isoforms governs cell tropism and host adaptation of influenza virus","volume":"2","author":"Gabriel","year":"2011","journal-title":"Nat. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ajpath.2016.12.017","article-title":"H7N9 Influenza A Virus Exhibits Importin-alpha7-Mediated Replication in the Mammalian Respiratory Tract","volume":"187","author":"Bertram","year":"2017","journal-title":"Am. J. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Bassetto, M., Cima, C.M., Basso, M., Salerno, M., Schwarze, F., Friese, D., Bugert, J.J., and Brancale, A. (2020). Novel Nucleoside Analogues as Effective Antiviral Agents for Zika Virus Infections. Molecules, 25.","DOI":"10.3390\/molecules25204813"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genom. Proteom. Bioinform."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"16897","DOI":"10.1074\/jbc.RA119.010214","article-title":"2\u2032-C-methylated nucleotides terminate virus RNA synthesis by preventing active site closure of the viral RNA-dependent RNA polymerase","volume":"294","author":"Boehr","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"13745","DOI":"10.1021\/acs.jmedchem.0c01293","article-title":"\u03b3-Ketobenzyl-Modified Nucleoside Triphosphate Prodrugs as Potential Antivirals","volume":"63","author":"Nack","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fmicb.2019.00039","article-title":"Influenza Virus Neuraminidase Structure and Functions","volume":"10","author":"McAuley","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.antiviral.2016.06.001","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015","volume":"132","author":"Hurt","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"19784","DOI":"10.2807\/ese.16.05.19784-en","article-title":"Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010\/11","volume":"16","author":"Lackenby","year":"2011","journal-title":"Euro. Surveill."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1128\/JVI.03513-14","article-title":"Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses","volume":"89","author":"Marjuki","year":"2015","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"30445","DOI":"10.2807\/1560-7917.ES.2017.22.3.30445","article-title":"Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014","volume":"22","author":"Trebbien","year":"2017","journal-title":"Euro. Surveill."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant data","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_45","first-page":"799","article-title":"Antiviral Medications in Seasonal and Pandemic Influenza","volume":"113","author":"Lehnert","year":"2016","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"Noshi","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1800698","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800698","article-title":"Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018","volume":"24","author":"Takashita","year":"2019","journal-title":"Euro. Surveill."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"22063","DOI":"10.1002\/anie.202003073","article-title":"Prodrugs of gamma-Alkyl-Modified Nucleoside Triphosphates: Improved Inhibition of HIV Reverse Transcriptase","volume":"59","author":"Zhao","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3851\/IMP2672","article-title":"Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and Favipiravir","volume":"23","author":"Cao","year":"2014","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1073\/pnas.0909603107","article-title":"T-705 (Favipiravir) activity against lethal H5N1 influenza A viruses","volume":"107","author":"Kiso","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1128\/AAC.01051-06","article-title":"Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice","volume":"51","author":"Sidwell","year":"2007","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s10096-020-03840-9","article-title":"Influenza and antiviral resistance: An overview","volume":"39","author":"Lampejo","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Smyk, J.M., Szydlowska, N., Szulc, W., and Majewska, A. (2022). Evolution of Influenza Viruses-Drug Resistance, Treatment Options, and Prospects. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012244"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1073\/pnas.1811345115","article-title":"The mechanism of resistance to Favipiravir in influenza","volume":"115","author":"Goldhill","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.antiviral.2016.06.007","article-title":"Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of Favipiravir","volume":"132","author":"Takashita","year":"2016","journal-title":"Antivir. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"26742","DOI":"10.1038\/srep26742","article-title":"Combinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in Mice","volume":"6","author":"Marathe","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Koszalka, P., Subbarao, K., and Baz, M. (2022). Preclinical and clinical developments for combination treatment of influenza. PLoS Pathog., 18.","DOI":"10.1371\/journal.ppat.1010481"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1473-3099(22)00212-2","article-title":"Is combination antiviral therapy for influenza the optimal approach?","volume":"22","author":"Lampejo","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Checkmahomed, L., Padey, B., Pizzorno, A., Terrier, O., Rosa-Calatrava, M., Abed, Y., Baz, M., and Boivin, G. (2020). In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses. Viruses, 12.","DOI":"10.3390\/v12101139"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.00933-09","article-title":"Effects of the combination of Favipiravir (T-705) and oseltamivir on influenza A virus infections in mice","volume":"54","author":"Smee","year":"2010","journal-title":"Antimicrob. Agents. Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/infdis\/jiz656","article-title":"Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients With Influenza Virus Infection","volume":"221","author":"Wang","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.antiviral.2012.03.001","article-title":"Combinations of Favipiravir and peramivir for the treatment of pandemic influenza A\/California\/04\/2009 (H1N1) virus infections in mice","volume":"94","author":"Tarbet","year":"2012","journal-title":"Antivir. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00404-022-06615-z","article-title":"The outcomes of Favipiravir exposure in pregnancy: A case series","volume":"307","author":"Ertem","year":"2022","journal-title":"Arch. Gynecol. Obs."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejogrb.2021.12.001","article-title":"Favipiravir exposure and pregnancy outcome of COVID-19 patients","volume":"268","author":"Tirmikcioglu","year":"2022","journal-title":"Eur. J. Obs. Gynecol. Reprod. Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/s41564-018-0236-1","article-title":"Male offspring born to mildly ZIKV-infected mice are at risk of developing neurocognitive disorders in adulthood","volume":"3","author":"Speiseder","year":"2018","journal-title":"Nat. Microbiol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/6\/1732\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:54:58Z","timestamp":1760126098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/6\/1732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,14]]},"references-count":65,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["pharmaceutics15061732"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15061732","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,14]]}}}